<DOC>
	<DOCNO>NCT00571688</DOCNO>
	<brief_summary>This study evaluate relative effectiveness risperidone Consta injection occur every 2 week contrast treatment usual preventing symptomatic relapse rate rehospitalization admission respite care bipolar patient . Hypothesis : Risperdal Consta injection every 2 week reduce number symptomatic relapse mania , hypomania , mixed state , depression , show key indicator include symptomatic relapse , rehospitalizations , emergency urgent care visit , respite care , intensive outpatient treatment compare treatment usual .</brief_summary>
	<brief_title>Does Risperidone Consta Reduce Relapse Rehospitalization Bipolar Disorder ?</brief_title>
	<detailed_description>Bipolar disorder arguably represent difficult treat psychiatric disorder . In fact , long-term stabilization exception rule , majority patient experience frequent relapse illness . Studies show bipolar I II patient spend half week significant symptomatic state . Relapses persistent illness result substantial morbidity , mortality , disability . Symptomatic recurrence happen result breakthrough symptom active treatment intermittent non-adherence . Therefore , enhance control symptom , couple ensure adherence , likely improve long-term outcome difficult-to-treat condition . Risperidone show effective controlling symptom acute mania mixed state two registration monotherapy one combination treatment study lithium valproate , well several small trial . However , longer-term treatment study relatively lack . As well , although Risperdal Consta ( TM ) show benefit prevention relapse patient schizophrenia , relatively little longer-term data bipolar disorder available . Nonetheless , risperidone Risperdal Consta ( TM ) likely highly efficacious maintenance prevention relapse bipolar disorder . Moreover , Risperdal Consta ( TM ) help ensure longer-term treatment effectiveness , good adherence improve control symptom . The present study intend determine whether Risperdal Consta ( TM ) injection , add ongoing pharmacotherapy , improve outcome relative treatment usual .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Be physically healthy 1860 year age Have DSMIV diagnosis bipolar disorder phase , without current psychotic feature ; history symptomatic relapse four occasion last year prior initiation study treatment bipolar disorder ( type I II , manic , hypomanic , mixed , depressive type ) , least 1 previous 6 month . Have screen HAMD17 score &gt; 8 YMRS &gt; 8 . Have medical condition would preclude treatment Risperdal Consta ( TM ) Have type 2 diabetes Have hyperlipidemia ( baseline total cholesterol &gt; 280 ) Have clinically significant unstable medical condition Have currently active psychotic symptom ( hallucination delusion ) carry diagnosis another psychotic disorder ( schizophrenia , schizoaffective disorder , delusional disorder ) Have documentable history nonresponse Risperidal Consta ( TM ) Have score 4 suicide item ( item 3 ) HAMD scale and/or determination investigator significant suicide risk Require hospitalization screen baseline visit , require hospitalization immediately follow baseline Have medical contraindication hypersensitivity risperidone Risperdal Consta ( TM )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression , Bipolar</keyword>
	<keyword>Mania</keyword>
</DOC>